biostudies-literatureHappe MNCI NIH HHSDivision of Intramural Research, National Institute of Allergy and Infectious Diseases67https://www.ebi.ac.uk/biostudies/studies/S-EPMC10980745biostudies-literatureUnknown9(1)Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). Trial US (NCT02408913) enrolled 140 participants, including 26 EVD vaccine-naïve and 114 cAd3-Ebola-experienced participants (April-November 2015). Trial UG (NCT02354404) enrolled 90 participants, including 60 EVD vaccine-naïve NPJ vaccinesHeterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.PMC1098074575N91019D00024Nesheim WDropulic LKKelley CFCarr DCourneya JHu ZGrimes VZephir KLStrom LPloquin ACostner PJMNakibuuka LDeCederfelt HKimbugne GGordon IJAnanworanich JLarkin BSullivan NJChen GLChrisley LXu JBeck AGirmay TSanders JLedgerwood JEChen WHMulligan MJNakabuye INovik LCampbell JDLee MStanley DAStein JGaudinski MRKoup RABerkowitz NMBillington MWhalen WRAshman CHofstetter ARBailer RTLuzinda KCham FCasazza JPGreenberg NKamya MRKwon AMascola JRKajumba FHappe MMichael NLSitar SOsinski ESadowski JKiweewa FMurray TPlummer SHStraling JWang JCoates EEKaltovich FDeZure ARouphael NTsukerman SKibuuka HWang XMendoza FPittman IRWakabi SOgilvie MDorsey BLyke KEMwesigwa BEnama MEHendel CSBailey CAHouser KVBecker JVRC 208 and RV 422 study teamBower MKomninou PEdupuganti SNguyen TATindikahwa AVasilenko OMatovu RKabbani SSchwartz RAke JAMukyala MGHolman LAMillard MGraham BSConan-Cibotti MKabahubya MRobb MLYamshchikov GVLai LfalseHeterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). Trial US (NCT02408913) enrolled 140 participants, including 26 EVD vaccine-naïve and 114 cAd3-Ebola-experienced participants (April-November 2015). Trial UG (NCT02354404) enrolled 90 participants, including 60 EVD vaccine-naïve 2024-01-01T00:00:00Z2024 Mar2026-06-01T21:47:49.977Z2025-04-22T08:17:26.526ZS-EPMC109807453855352510.1038/s41541-024-00833-z